| |
NSCLC Patients (N=40) |
Controls (N=15) |
P-value |
| Age (years) |
| Mean ± SD |
62.33 ± 8.08 |
58. 4 ± 8.26 |
0.178 |
| Gender |
| Males |
30 (75%) |
9 (60%) |
0.345 |
| Females |
10 (25%) |
6 (40%) |
| Smoking |
| Yes |
30 (75%) |
8 (53.4%) |
0.345 |
| No |
10 (25%) |
7 (46.6%) |
| Mean Pack-yr |
| <10 |
19 (47.5%) |
7 (46.6%) |
0.355 |
| ≥ 10 |
21 (52.5%) |
8 (53.4%) |
| Histopathology of NSCLC |
| Squamous cell carcinoma |
18 (45%) |
- |
- |
| Adenocarcinoma |
22 (55%) |
- |
| Stages of NSCLC |
| II |
7 (17.5%) |
- |
- |
| III |
24 (60%) |
- |
| IV |
9 (22.5%) |
- |
| Objective Radiological Response |
| Complete response |
0 |
- |
- |
| Partial response |
20 (50%) |
- |
| No change |
4 (10%) |
- |
| Progressive disease |
16 (40%) |
- |
| CYFRA 21-1 level (ng/ml) |
| Pre-treatment level |
8.13 ± 11.92 |
0.56 ± 0. 2 |
0.001 |
| After 2 cycles of chemotherapy |
7.54 ± 11.6 |
- |
| CEA level (ng/ml) |
| Pre-treatment level |
28.26 ± 56.72 |
0.2 ± 0.13 |
0.001 |
| After 2 cycles of chemotherapy |
21.68 ± 41.77 |
- |
| Survival |
| Alive |
26 (65%) |
- |
- |
| Dead |
14 (35%) |
- |
|
